Clinical trials: Hepatitis C, Chronic
Hepatitis C, Chronic, Genotype 1
Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)
The primary objective of this study is to evaluate the impact of chronic hepatitis C (CHC), and the treatment thereof with peginterferon alpha-2b (PEG) and ribavirin (RBV) according to standard clinical practice, on the…
- Conditions
- Hepatitis C, Chronic, Genotype 1, HCV-1
- Trial name
- VIDA (NCT00863109)
- Testing
- Peginterferon alfa-2b (PEG), Ribavirin (RBV)
- Volunteers
- 133 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus (HCV)
Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection
This study will evaluate the efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian participants with compensated cirrhosis with or without human…
- Trial name
- VOYAGE-2 (NCT03235349)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 34 sites in China, South Korea
- Volunteers
- 160 people
- Sponsor
- AbbVie
Hepatitis C
A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)
This is a study of the safety and efficacy of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) ± ribavirin (RBV). The primary efficacy endpoint will be Sustained Virologic Response 12 weeks after the end of all study…
- Trial name
- C-WORTHy (NCT01717326)
- Testing
- Grazoprevir, Elbasvir, Ribavirin
- Volunteers
- 573 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C
The purpose of this study is to determine the safety and tolerability of bavituximab when administered via an arm vein as multiple infusions and to examine how bavituximab behaves in the body and how it effects the amount of…
- Trial name
- NCT00343525
- Testing
- bavituximab
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Peregrine Pharmaceuticals
Chronic Hepatitis C
Antioxidant and Immunomodulator Properties of Viusid in Patients With Chronic Hepatitis C
The pathogenesis of chronic hepatitis C (CHC) is associated to severe oxidative stress and non-selective immunological disturbance that leads to necro-inflammation and progression of fibrosis.
- Trial name
- NCT00778843
- Testing
- Viusid
- Where
- Cuba
- Volunteers
- 60 people
- Sponsor
- Catalysis SL
Hepatitis C
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
The purpose of this study is to demonstrate the efficacy of TMC435 in combination with peginterferon (PegIFN) + ribavirin (RBV) by means of establishing its non- inferiority compared to an approved regimen of telaprevir + PegIFN…
- Trial name
- ATTAIN (NCT01485991)
- Testing
- TMC435, TVR
- Where
- 137 sites in United States, Argentina and 22 more
- Volunteers
- 771 people
- Sponsor
- Janssen R&D Ireland
Chronic Hepatitis C Virus
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
The purpose of this study is to evaluate the safety and efficacy of a quadruple regimen (VX-222, telaprevir, pegylated interferon, and ribavirin)in subjects with hepatitis C with cirrhosis.
- Trial name
- NCT01516918
- Testing
- VX-222, telaprevir, ribavirin
- Where
- 43 sites in United States, Canada and 3 more
- Volunteers
- 103 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis C, Chronic
A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
This multi-center, open-label study will evaluate the efficacy and safety of Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) in relation to IL28-b gene expression in treatment-naïve patients with chronic hepatitis C…
- Trial name
- NCT01447420
- Testing
- peginterferon alfa-2a, ribavirin [Copegus]
- Where
- 15 sites in Brazil
- Volunteers
- 129 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C
Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects
A multi-part study to evaluate the safety and PK of single ascending doses of IDX21549 in healthy and HCV-infected subjects. The effect of food on the PK of IDX21549 will also be evaluated.
- Trial name
- NCT02112942
- Testing
- IDX21459
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
The purpose of this study is to investigate the efficacy and safety of TMC435 plus PSI-7977 (GS7977) with or without ribavirin in patients who are chronically infected with genotype 1 hepatitis C virus (HCV) and who did not…
- Trial name
- COSMOS (NCT01466790)
- Testing
- TMC435, PSI-7977 (GS7977), Ribavirin
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 168 people
- Sponsor
- Janssen R&D Ireland
Chronic Hepatitis C
A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus
The purpose of this study is to explore the efficacy and safety of TMC647055, TMC435, and low-dose ritonavir, administered together with and without ribavirin and of TMC647055, TMC435, low-dose ritonavir administered together…
- Trial name
- NCT01724086
- Testing
- TMC647055, TMC435, Ritonavir
- Where
- 10 sites in Belgium, Germany
- Volunteers
- 90 people
- Sponsor
- Janssen R&D Ireland
Chronic Hepatitis C
Study of Nitazoxanide Combined With Peginterferon Compared to Peginterferon Monotherapy in the Treatment of Hepatitis C
The purpose of this study is to evaluate the safety and efficacy of nitazoxanide-peginterferon alfa-2b combination therapy compared to peginterferon monotherapy in patients that are treatment naive or pre-treated for 24 weeks…
- Trial name
- NCT00418054
- Testing
- Nitazoxanide plus peginterferon alfa-2b, Peginterferon alfa-2b
- Where
- 2 sites in Egypt
- Volunteers
- 40 people
- Sponsor
- Romark Laboratories L.C.
Chronic Hepatitis C Virus (HCV) Infection
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection
The purpose of this study is to assess the efficacy and safety of 12 weeks of treatment with the ABT-493/ABT-530 combination regimen in adults with chronic HCV genotype 1 - 6 infection and chronic severe renal impairment.
- Trial name
- EXPEDITION-4 (NCT02651194)
- Testing
- ABT-493/ABT-530
- Volunteers
- 104 people
- Sponsor
- AbbVie
Hepatitis C
Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)
This is a study of grazoprevir (MK-5172) + elbasvir (MK-8742) and sofosbuvir (SOF) in treatment-naive participants with chronic hepatitis C (HCV) genotype (GT) 1 or GT3.
- Trial name
- NCT02133131
- Testing
- Grazoprevir/Elbasvir FDC, Sofosbuvir
- Volunteers
- 143 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation
The purpose of the study is to evaluate effect of steady-state (when the amount of drug administered (in a given time period is equal to the amount of drug eliminated in that same period) of simeprevir and daclatasvir on the…
- Trial name
- NCT01938625
- Testing
- Simeprevir, Daclatasvir, Ribavirin
- Where
- 6 sites in Germany, Poland and 1 more
- Volunteers
- 35 people
- Sponsor
- Janssen R&D Ireland
Hepatitis C
TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients
The purpose of this study is to assess the safety and tolerability of TMC647055 both after increasing single oral doses from 100 mg up to maximum 3000 mg in fed conditions, and after multiple oral doses in fed conditions at…
- Trial name
- NCT01202825
- Testing
- TMC647055, TMC435
- Where
- Belgium
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Chronic Hepatitis C, Genotype 1
Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation
This study seeks to assess the effectiveness, patient reported outcomes, work productivity and healthcare resource utilization of the interferon-free regimen of paritaprevir /ritonavir (r) - ombitasvir, ± dasabuvir ± ribavirin…
- Trial name
- HCV RWE (NCT02669940)
- Volunteers
- 158 people
- Sponsor
- AbbVie
Hepatitis C Virus (HCV)
Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C
The purpose of this study is to determine if 48 weeks of therapy with Peginterferon Lambda plus Ribavirin is effective and safe for a treatment of chronic hepatitis C (CHC) compared to therapy with Peginterferon alfa-2a plus…
- Trial name
- BASIS (NCT01754974)
- Testing
- Peginterferon Lambda-1a, Ribavirin, Peginterferon alfa-2a
- Where
- 16 sites in Czechia, Mexico and 1 more
- Volunteers
- 40 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection
The purpose of this study is to determine whether 24 weeks of Daclatasvir and Sofosbuvir with Ribavirin is safe and effective in the treatment of genotype 3 hepatitis C infected patients with liver cirrhosis.
- Trial name
- NCT02673489
- Testing
- DCV, SOF, RBV
- Where
- 19 sites in United States, Canada
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy
The purpose of this study is to determine if treatment with Pegylated Interferon Lambda-1a, given in combination with Ribavirin and Daclatasvir for 24 weeks, is as safe and effective as the standard treatment with Pegylated…
- Trial name
- STRUCTURE (NCT01718158)
- Testing
- Peginterferon Lambda-1a, Peginterferon Alfa-2a, Ribavirin
- Where
- 78 sites in United States, Argentina and 11 more
- Volunteers
- 444 people
- Sponsor
- Bristol-Myers Squibb